ALKBH5 insufficiency protects against ferroptosis-driven cisplatin-induced renal cytotoxicity Authors: Yu Zhu, Yanyan Jin, Xue He, JunYi Chen, Yao Zhang, JingJing Wang Published: 2024 ABSTRACT In the clinical setting, cisplatin-induced nephrotoxicity primarily manifests as acute kidney injury (AKI). Recent studies have indicated that ferroptosis, a type of iron-dependent cell death, is closely involved in the cisplatin nephrotoxicity. AlkB homologue 5 (ALKBH5), an N6-methyladenosine (m6A) eraser protein expressed in various tissues, including the kidneys, has been implicated in this process. However, the specific role of ALKBH5 in cisplatin-induced nephrotoxicity remains unknown. Our findings indicated that ALKBH5 was upregulated in cisplatin-induced AKI, and the in vivo study results were consistent with the results of the in vitro study. Additionally, ALKBH5 knockout in transgenic animals was found to mitigate cisplatin-induced renal dysfunction, whereas its knock-in exacerbated the effects. Our study revealed that ALKBH5 controls the traditional ferroptosis metabolic pathway, leading to worsening of AKI in experiments conducted both in vivo and in vitro. The efficacy of pharmacological intervention targeting ALKBH5 in AKI animal models was demonstrated, and ALKBH5-based gene therapy confirmed these findings and displayed renoprotective effects against AKI. In conclusion, this study highlighted the crucial role of ALKBH5 as a key regulator of AKI. Overall, our research demonstrates the significant impact of ALKBH5 in controlling ferroptosis in cisplatin-induced AKI, suggesting that focusing on ALKBH5 could be a promising approach for treating cisplatin-related kidney damage.Graphical Abstract Introduction Acute kidney injury (AKI) encompasses a range of clinical syndromes resulting from various etiological factors and is distinguished by the rapid deterioration of renal function (Roth et al. 2024). With the increase in tumor incidence, the occurrence of AKI caused by antineoplastic drug treatment has also increased annually (Zheng et al. 2024). Given its widespread occurrence, substantial treatment expenses, and high mortality rates, AKI is a pressing global health concern. According to data from the International Society of Nephrology, an estimated 13.3 million individuals worldwide experience acute kidney injury (AKI) annually, with 39% affecting adults and 53% affecting children. Consequently, the international society of Nephrology has launched the "0 by 25" initiative, urging global efforts, particularly in developing nations, to enhance the identification and management of AKI with the goal of eliminating all preventable AKI-related fatalities by the year 2025. Cisplatin (DDP), a well-established chemotherapeutic agent, is commonly used to manage solid tumors affecting multiple organ systems, notably the kidneys (Li et al. 2024). Nevertheless, DDP administration is often associated with the development of acute kidney injury (AKI), a primary factor contributing to the heightened vulnerability of cancer patients to AKI (Patel et al. 2024). The precise pathophysiological mechanisms underlying DDP-induced AKI remain unclear, limiting the availability of effective clinical strategies for its prevention and management. Damage to renal tubules is a crucial factor in the development and progression of DPP-induced AKI caused by DDP (Nguyen et al. 2024). Prior research on DDP-AKI has emphasized the mechanisms of apoptosis and necrosis in renal tubular cells (Mansoure et al. 2024; Huang et al. 2024). However, targeted inhibitors of these processes have shown limited efficacy in inhibiting cisplatin-induced cell death in mice. Ferroptosis, another type of cell death, has been linked to DDP-induced tissue damage, especially in the kidneys (Chen et al. 2024). Therefore, it is imperative to further investigate the role of DDP-induced ferroptosis in the pathogenesis of DDP-AKI for clinical implications. Unlike apoptosis, autophagy, and necrosis, ferroptosis is a recently discovered iron-dependent programmed cell death. During ferroptosis, the SLC7A11 (Solute Carrier Family 7 Member 11, also known as xCT) system is inhibited, resulting in lower glutathione (GSH) levels and suppression of glutathione peroxidase 4 (GPX4), which leads to an increase in reactive oxygen species (ROS) and build-up of lipid peroxidation (Mishima 2024). Epigenetic modifications control gene expression without altering DNA sequences. Dynamic changes affect a range of biological functions including gene regulation, protein activity, aging, and disease development (Wang et al. 2023). There are various ways to modify RNA; however, the most common is using N6-methyladenosine (m6A), which methylates adenylate at the sixth position. The process of m6A modification is both dynamic and reversible, and is primarily controlled by m6A methyltransferases, m6A methylation recognition proteins, and m6A demethylases. These components function together to regulate RNA methylation (Li et al. 2024). ALKBH5, an m6A eraser protein, is known for its direct removal of m6A modifications (Huang et al. 2024). Although ALKBH5 has been linked to the pathogenesis of renal diseases, such as ischemia–reperfusion injury (Chen et al. 2023), the specific pathogenic role and mechanisms of ALKBH5 in DDP-induced AKI are poorly understood. Our research shows that the upregulation of ALKBH5 after cisplatin treatment plays a role in the development of AKI via ferroptosis-related pathways. Materials and methods Animal model and drug administration The mice (12–16 weeks old) used for the experiment were housed in typical laboratory enclosures with four to five mice in each enclosure. They were exposed to a 12-h light/dark cycle, (lights on at 08:00) at a temperature of 21–25 °C and humidity at 45–55%. Food and water were provided ad libitum, and the experiments were carried out following the regulations set by the Chinese Council on Animal Care. Attempts were made to reduce the pain experienced by the animals and decrease the number of animals used. Experiments adhered strictly to the regulations set forth by the Animal Ethics Committee of Zhejiang University. Both sexes were used in the DDP experiments in a sex-balanced manner, and sex differences were examined using chi-squared analyses. ALKBH5 knockout mice (ALKBH5−/−) and ALKBH5-knock-in mice (ALKBH5+/+) and their wild type (WT) controls were provided by Gem Pharmatech (Nanjing, China) and generated using a conventional homologous recombination gene-targeting strategy (Chen et al. 2023) Successful knock-in was validated by sequencing genomic DNA from the knock-in mouse. At least ten generations of backcrossing were performed to obtain animals with a C57/BL6 background. To induce AKI, 20 mg/kg body weight DDP dissolved in 0.9% NaCl solution (P4394, Sigma-Aldrich, St. Louis, MO) was administered intraperitoneally, following a previously described protocol (Hou et al. 2022). The ALKBH5 inhibitors DDO-2728 (20 mg/kg) and IOX1 (20 mg/kg) (Selleck Chemicals (Houston, TX, USA)) were dissolved in dimethyl sulfoxide (DMSO) and administered to mice by intraperitoneal injection for three consecutive weeks before DDP administration (Lee et al. 2021; Sun et al. 2023). Cell culture and transfection The human renal proximal tubular epithelial HK-2 cells were purchased from ProCell Life Sciences and Technology (Wuhan, China). HK-2 cells were cultured in RPMI 1640 and DMEM from Invitrogen (Shanghai, China), supplemented with 100 µg of penicillin G, 100 µg of streptomycin, and 10% FBS. As indicated by the experimental setup, HK-2 cells were treated with 2 µg/mL of DDP and collected at various time points. Erastin, a compound that induces ferroptosis, and Fer-1, a ferroptosis inhibitor, were bought from Selleck Chemicals. The iron-chelating drug, deferiprone (DFP), was purchased from Sigma-Aldrich. To analyze cell ferroptosis, cells were placed in 6-well plates at a density of 2.5 × 105 cells per well and exposed to erastin (10 µM), Fer-1 (1 μM), DFP (500 μM), and DDP for 24 h. The ALKBH5 overexpression plasmid (ALKBH5-OE), knockout plasmid (ALKBH5-shRNA), and empty vector plasmid (empty vector) were acquired from the MiaoLing Plasmid Platform (Wuhan, China). HK-2 cells were transfected with either 1 μg pVector or 1 μg plasmids using Lipofectamine 2000, following the manufacturer’s guidelines (12566014, Invitrogen). Renal function analysis Mice were anesthetized, and blood was collected from the orbital plexus. Blood samples were spun at 3000 rpm at 4 °C for 10 min to collect serum, which was then stored at -20 °C until required. Mice kept overnight in metabolic cages were sampled for their urine. Measurements of blood urea nitrogen were performed using a QuantiChrom Urea Assay kit (BioAssay Systems, CA, United States). Serum creatinine levels were measured using a creatinine kit (iSTAT, Abbott Point-of-Care, USA). Using a Roche automatic biochemical analyzer, the ratio of albumin to creatinine in urine (ACR) was determined by dividing the amount of albumin by the amount of creatinine (μg/g). Histological and immunohistochemical analysis Kidney tissue was collected after intraperitoneal administration of 1% sodium pentobarbital under sodium anesthesia and perfusion with 4% paraformaldehyde (PFA). The animals were sacrificed by decapitation. Formalin-fixed paraffin-embedded kidney sections were used for immunohistochemical analyses. Using immunohistochemistry, the ROS marker 8-hydroxyguanosine (8-OHG) was detected in kidney tissues. Kidney samples were rinsed twice with PBS, then immersed in 4% paraformaldehyde for two days, followed by dehydration, paraffin embedding, and slicing into 5 μm sections. Following antigen blocking, the sections were then treated with the corresponding primary antibody (anti-ALKBH5, ab195377, 1:3000; anti-malondialdehyde, ab243066, 1:1000; anti-4 hydroxynonenal, ab48506, 1:2000; anti-8-OHG, ab10802, 1:500) from Abcam (Cambridge, UK) overnight at 4 °C, followed by incubation with HRP-conjugated antibody targeting rabbit IgG and DAB as the chromogen. Whole slides were digitally scanned and imaged using a BX53 microscope (Olympus) at 40 × objective magnification, under the supervision of a pathologist. The expression level of immunohistochemical staining was evaluated based on the staining intensity and percentage of positive cells from the total slides. To determine the staining intensity of tissue sections, ImageJ (NIH; Bethesda, MD, USA) was used, equipped with ImmunoRatio (ER/PR analysis) and ImmunoMembrane (HER-2 analysis) plugins. In each case, the immunoglobulin pixel intensity measurements were normalized to the staining intensity in the corresponding controls. Western blot In this study, whole proteins were extracted from tissues using the Tissue Protein Extraction Reagent (Thermo Fisher, Waltham, MA, USA), whereas whole cellular proteins were extracted using the Mammalian Protein Extraction Reagent (Thermo Fisher). The specimens were heated at 95 °C for 10 min before being placed onto the SDS-PAGE gel. After electrophoresis, membrane transfer, and blocking, the specimens were incubated with primary antibodies overnight at 4 °C. Primary antibodies including anti-ALKBH5(1:300, #80283S), anti-GAPDH (1:500, #5174S), anti-GPX4 (1:200, #52455), anti-Tfrc (1:200, #46222), anti-FTH (1:500, #3998), and anti-SLC7A11 (1:600, #98051) were obtained from Cell Signaling Technology (Danvers, MA, USA). SAMples were then incubated with horseradish peroxidase (HRP)-linked secondary antibodies (BioRad, Hercules, CA, USA, Cat. nos. 1721019 and 1706516; 1:1000) at room temperature for one hour, followed by detection using enhanced chemiluminescence with either SuperSignal West Dura or Femto Chemiluminescent Substrate (Thermo Fisher). The membranes were imaged and visualized using a ChemiDoc MP Imaging System with ImageLab 5.0 software (Bio-Rad). Protein bands were quantified by measuring the peak area using the ImageJ software (NIH, https://imagej.nih.gov/ij/). Real-time quantitative PCR (RT-qPCR) RT-qPCR was conducted to analyze RNA isolation and expression in the collected samples following previously described methods (Tian et al. 2024). Following the specified treatment, total RNA was isolated from the cells using TRIzol reagent (Thermo Fisher) following standard procedures. Complementary DNA (cDNA) was synthesized using HiScript III RT SuperMix for qPCR (Vazyme, Nanjing, China). The RT-qPCR conditions were: holding stage (95 °C for 10 min), cycling stage (40 cycles at 95 °C for 15 s and 60 °C for 1 min), and melt curve stage (95 °C for 15 s, 60 °C for 1 min, and 95 °C for 15 s). Quantitative PCR was performed using AceQ qPCR SYBR Green Master Mix from Vazyme, and the signals were detected using the CFX96 Touch sequence detection system from BioRad. Relative mRNA was quantified using the Eq. 2 − ΔΔCt. GAPDH was used as an internal control to determine relative fold changes in gene expression. MTT assay The viability of cells was determined using MTT assays (Roche Diagnostics GmbH, Mannheim, Germany). Twenty microliters of MTT reagent (5 mg/ml) was added to each well in a 96-well plate and incubated for 4 h. The reaction was stopped by adding 100 μL of dimethylsulfoxide (DMSO) and incubating at 37 °C in the dark for 10 min. Cell proliferation was evaluated by measuring the optical density (OD) at wavelengths of 570 nm and 630 nm. ELISA Tissue samples were analyzed according to the manufacturer’s instructions. The amounts of GSH and malondialdehyde (MDA) in the kidney tissues were measured using GSH (Solarbio) and MDA assay kits (Solarbio). The kits for measuring the levels of 4-hydroxynonenal (4-HNE) and total superoxide dismutase (SOD) activity were purchased from Nanjing Jiancheng Bioengineering Institute, (Nanjing, China). Detection and quantification limits were determined using signal-to-noise ratios (S/N). The intra- and inter-assay coefficients of variation for the ELISA concentrations were less than 5% per assay in all cases. Ferroorange stain Intracellular Fe2 + levels were measured using FerroOrange (Dojindo, Japan). A mixture of serum-free DMEM and the FerroOrange working solution was combined in a petri dish to reach a concentration of 1 µg of FerroOrange in the base medium. The cells were incubated in darkness for 30 min in an incubator. The red fluorescence intensity was then observed directly using a fluorescence microscope. FerroOrange has an excitation wavelength of 561 nm and emission range of 570–620 nm. Iron content In brief, kidney samples were washed with PBS and digested with 5% HNO3 at 60 °C for 2 h. The supernatant was collected for iron analysis by flame atomic absorption spectrometry with acetylene-air flame atomization (AAS, AA800, Perkin Elmer, Shelton, CT, USA). A Varian atomic absorption spectrometer (Varian, Mulgrave, Australia) equipped with a deuterium background correction was used for the analysis. The measurements were performed at a wavelength of 248.3 nm within a spectral range of 0.2 nm. Iron concentration was quantified using the standard addition method, and each measurement series included internal quality controls to guarantee test reliability. Adeno-associated virus (AAV) packaging and injection Because AAV (serotype 9) is highly infective and stable, it was used to package recombinant AAV (Peng et al. 2020). Expression is controlled by the CMV promoter, which has been used to successfully target the renal tissue of interest. AAV9 with ALKBH5-shRNA or control-shRNA was created using the pAAV9-CMV-EGFP system from OBIO (Shanghai, China) following the manufacturer's instructions. Animals receiving AAV were injected with a single bolus injection resuspended in PBS via the left renal vein at a dose of 1 × 1011 viral genomes per animal for in vivo transduction (Ortiz-Muñoz et al. 2010). For verification of viral infection after experiments, frozen kidney sections were prepared and sliced at a thickness of 50 μm. Cellular nuclei of renal sections were stained with DAPI (Invitrogen). Fluorescent images were captured using an Olympus BX53 microscope (Tokyo, Japan). Statistical analyses No predetermined method was used to determine the optimal sample size or to randomly allocate subjects to the experimental groups. The sample sizes closely resembled those reported in prior studies. The Shapiro–Wilk normality test confirmed that the data distribution was within normal limits, and statistical differences of normally distributed data were determined using one-way ANOVA followed by post hoc Bonferroni analysis or Student’s t-test. All data were analyzed using SPSS software. P values less than 0.05 were considered statistically significant. P values less than 0.05 were expressed as *p < 0.05, those less than 0.01 as **p < 0.01, and those less than 0.001 as ***p < 0.001, respectively. Results ALKBH5 levels are elevated in conjunction with DDP-induced nephropathy in both experimental models and cell cultures To establish an experimental murine nephropathy model, mice were injected with DDP (Fig. 1A), and blood and kidney tissues were collected for biochemical analysis. Renal-function-related physiological indices were compared among the groups to validate the method. DDP administration significantly increased plasma urea nitrogen (Fig. 1B), plasma creatinine (Fig. 1C), and urinary albuminuria/creatinine ratio (Fig. 1D). ALKBH5 mRNA and protein extracted from the renal tissues of each group were analyzed using RT-qPCR and western blotting. ALKBH5 mRNA and protein expression significantly increased with longer DDP treatment time (Fig. 1E, F). Moreover, ALKBH5 expression in mouse renal tissue was investigated using immunohistochemistry, and DDP treatment upregulated ALKBH5 expression in the tubular tissue (Fig. 1G). After confirming our in vivo findings, we verified our hypothesis in vitro using human tubular HK-2 cells. ALKBH5 expression was very low in untreated cultured HK-2 cells; however, after DDP treatment, ALKBH5 expression increased significantly(Fig. 1H, I). Based on these results, ALKBH5 appears to aggravate DDP-induced renal injury.Fig. 1The expression of ALKBH5 upon DDP administration on renal ALKBH5 expression was investigated (A) Diagram of experimental design and timeline. (B-D) Blood urea nitrogen (B), creatinine (C) and uranary albuminuria/creatinine ratios (ACR) (D) were measured in plasma after 3 weeks of DDP tail vein administration. (E, F) The levels of ALKBH5 mRNA and protein were measured at the indicate time points. (G) Immunohistochemical localisation of ALKBH5 expression in the kidney tissues.Scale bar: 20 µm. (H) Statistical analysis of ALKBH5 expression at different times following DDP treatment in podocytes. (I) Cells were fixed and co-stained for ALKBH5 (green immunofluorescence) and DAPI (blue immunofluorescence). The data is displayed as the average plus or minus the standard deviation. Significance levels: p < 0.05, p < 0.01, p < 0.001 The expression of ALKBH5 upon DDP administration on renal ALKBH5 expression was investigated (A) Diagram of experimental design and timeline. (B-D) Blood urea nitrogen (B), creatinine (C) and uranary albuminuria/creatinine ratios (ACR) (D) were measured in plasma after 3 weeks of DDP tail vein administration. (E, F) The levels of ALKBH5 mRNA and protein were measured at the indicate time points. (G) Immunohistochemical localisation of ALKBH5 expression in the kidney tissues.Scale bar: 20 µm. (H) Statistical analysis of ALKBH5 expression at different times following DDP treatment in podocytes. (I) Cells were fixed and co-stained for ALKBH5 (green immunofluorescence) and DAPI (blue immunofluorescence). The data is displayed as the average plus or minus the standard deviation. Significance levels: p < 0.05, p < 0.01, p < 0.001 ALKBH5 mediates DPP-induced kidney injury Next, we examined the effects of ALKBH5 on kidney damage. Animal experiments were conducted to determine whether reducing ALKBH5 expression could prevent DDP-induced renal damage. Western blot analysis confirmed the successful depletion of ALKBH5 in the kidneys of ALKBH5-/- mice, which prevented the DDP-induced upregulation of ALKBH5 expression (Fig. 2A). Biochemical analyses indicated that ALKBH5 knockdown delayed the progression of renal dysfunction and protected renal function (Fig. 2B–D). DDP-induced kidney damage involves the markers of oxidative injury, ROS. ROS levels in the kidney were therefore measured using immunohistochemical analyses to detect cellular injury. ALKBH5 knockdown significantly decreased cellular ROS levels (Fig. 2E), indicating that ROS equilibrium is altered during ALKBH5 knockdown. Moreover, ALKBH5 overexpression had opposite effects to ALKBH5 knockout. Differential expression of ALKBH5 was observed between the knock-in and WT animals (Fig. 2F). Analysis of kidney function parameters showed that knock-in alone had no significant effect compared to the WT control group. However, after DDP administration, the renal tissue of the knock-in animals was more severely damaged (Fig. 2G–I). Additionally, increased ROS production was observed in knock-in mice (Fig. 2J).Fig. 2ALKBH5 mediates DDP-induced kidney injury. (A) Representative images of Western blots displaying the ALKBH5 expression. (B-D) Blood urea nitrogen (B), creatinine (C) and uranary albuminuria/creatinine ratios (ACR) (D) were measured in plasma after 3 days of DDP tail vein administration in the indicated groups. Immunohistochemical images and quantification of reactive oxygen species staining are presented by the representative.Scale bars, 20 μm. (F) Representative western blot images showing the expression of ALKBH5. (G-I) Blood urea nitrogen (G), creatinine (H) and uranary albuminuria/creatinine ratios(ACR) (I) were measured in plasma after 3 days of DDP tail vein administration in the indicated groups. Immunohistochemical images and quantification of staining for ROS were presented by the representative. Scale bars, 20 μm. The data is displayed as the average plus or minus the standard deviation. Significance levels: p < 0.05, p < 0.01, p < 0.001 ALKBH5 mediates DDP-induced kidney injury. (A) Representative images of Western blots displaying the ALKBH5 expression. (B-D) Blood urea nitrogen (B), creatinine (C) and uranary albuminuria/creatinine ratios (ACR) (D) were measured in plasma after 3 days of DDP tail vein administration in the indicated groups. Immunohistochemical images and quantification of reactive oxygen species staining are presented by the representative.Scale bars, 20 μm. (F) Representative western blot images showing the expression of ALKBH5. (G-I) Blood urea nitrogen (G), creatinine (H) and uranary albuminuria/creatinine ratios(ACR) (I) were measured in plasma after 3 days of DDP tail vein administration in the indicated groups. Immunohistochemical images and quantification of staining for ROS were presented by the representative. Scale bars, 20 μm. The data is displayed as the average plus or minus the standard deviation. Significance levels: p < 0.05, p < 0.01, p < 0.001 ALKBH5 knockout mediates DPP-induced kidney injury via inhibition of ferroptosis Research has indicated that in the presence of ROS, lipids on the cell membrane are peroxidized owing to ROS attack, which is the core feature of ferroptosis (Wang et al. 2022). However, whether ALKBH5 is involved in the process of DDP-mediated renal ferroptosis remains unclear. Therefore, we investigated whether ALKBH5 plays a role in ferroptosis initiation in DDP-treated kidneys. Atomic absorption spectroscopy revealed that the increase in kidney iron levels induced by DDP was significantly reduced in ALKBH5−/− mice (Fig. 3A). During ferroptosis, MDA accumulates as an end product of polyunsaturated fatty acid peroxidation. Simultaneously, 4-HNE expression increases. The presence of GSH is essential for protection against ferroptosis, because a decrease in GSH levels leads to an increase in ferroptosis susceptibility. Changes in SOD levels further indicated the presence of antioxidant responses. MDA and 4-HNE levels were increased when treated with DDP, whereas there was a marked decrease in SOD and GSH levels, as assessed using ELISA. These findings suggested that ferroptosis was the primary mechanism of cell death triggered by DDP (Fig. 3B–E). However, this effect was largely blocked in ALKBH5−/− mice. The IHC results further demonstrated that the elevated staining intensity of MDA-, 4-HNE-, and iron-positive renal tissues was largely reversed by ALKBH5 deletion (Fig. 3F–H). Furthermore, we delved deeper into the alterations in ferroptosis-associated controllers in each tissue group. In WT animals treated with DDP, the levels of GPX4, FTH, and SLC7A11 proteins in the kidneys were notably reduced compared to those in the control group, whereas the expression of Tfrc was significantly elevated. Interestingly, the expression levels of GPX4, FTH, SLC7A11, and Tfrc could be reversed in ALKBH5−/− mice (Fig. 3I). These data indicated that knockdown of ALKBH5 markedly decreased DDP-induced ferroptotic renal cell injury.Fig. 3ALKBH5 knockdown alleviated DDP-induced ferroptotic cell injury. (A) Atomic absorption spectrometry was used to measure the concentration of iron in the kidneys. (B-E) The concentrations of MDA (B), 4-HNE (C), SOD (D), and GSH (E) were measured in kidney tissues of mice. Representative immunohistochemical pictures and measurement of reactive oxygen species staining.Scale bars, 20 μm. (F-G) Immunohistochemical staining in kidney tissues for MDA (F) and 4-HNE (G). Scale bars, 20 μm. (H) Diaminobenzidine (DAB)-enhanced Perls staining for nonheme iron in kidney tissue.bScale bars, 20 μm. Quantification of immunoblots was performed with ImageJ and then standardized against GAPDH. The data is displayed as the average plus or minus the standard deviation.Significance levels: p < 0.05, p < 0.01, p < 0.001 ALKBH5 knockdown alleviated DDP-induced ferroptotic cell injury. (A) Atomic absorption spectrometry was used to measure the concentration of iron in the kidneys. (B-E) The concentrations of MDA (B), 4-HNE (C), SOD (D), and GSH (E) were measured in kidney tissues of mice. Representative immunohistochemical pictures and measurement of reactive oxygen species staining.Scale bars, 20 μm. (F-G) Immunohistochemical staining in kidney tissues for MDA (F) and 4-HNE (G). Scale bars, 20 μm. (H) Diaminobenzidine (DAB)-enhanced Perls staining for nonheme iron in kidney tissue.bScale bars, 20 μm. Quantification of immunoblots was performed with ImageJ and then standardized against GAPDH. The data is displayed as the average plus or minus the standard deviation.Significance levels: p < 0.05, p < 0.01, p < 0.001 The direct contribution of ferroptosis to DDP-induced tubular epithelial injury These results indicate that ALKBH5 is involved in the regulation of ferroptosis. However, there is no direct connection between DDP-induced podocyte injury and ferroptosis. We further validated this hypothesis by examining the regulation of ferroptosis. The loss of renal tubule epithelial cells is a key feature of AKI pathogenicity. Next, the responses of renal tubular epithelial cell lines to ferroptosis inducers and inhibitors were measured. Erastin initiates iron-dependent ferroptosis in mammalian cells. Moreover, we explored whether ferrostatin-1 (Fer-1) or the iron chelator, DFP, could reduce cell death. The MTT assay revealed that DDP decreased cell viability after 48 h of treatment, and co-treatment of cells with erastin during the last 12 h further decreased cell viability, while Fer-1 or DFP increased cell viability (Fig. 4A). We measured the release of lactate dehydrogenase (LDH), a biomarker of cytotoxicity, in damaged cells. The LDH release results supported this conclusion (Fig. 4B). Interventions targeting iron death affect expression of ferroptosis markers in cells. The changes in MDA, 4-HNE, and ROS levels demonstrated the success of the ferroptosis intervention strategy and were consistent with the changes in cell damage (Fig. 4C–E). In addition, we used the Fe2+ probe FerroOrange to label podocytes, which selectively interacts with Fe2+ rather than Fe3+, and observed a significant increase in the signal strength of FerroOrange in cells treated with DDP. FerroOrange staining showed that the erastin-induced increase in the labile iron concentration was alleviated by DFP/Fer-1 treatment (Fig. 4F). Western blot results for ferroptosis-related proteins were consistent with those observed in vivo (Fig. 4G). Taken together, these data suggest that ferroptosis induces DDP-induced kidney injury and that inhibitors of ferroptosis prevent DDP-induced cell damage.Fig. 4Ferroptosis contribute to DDP-induced podocyte injury (A) Cell viability were determined by the MTT assay. (B) Cell damage was measured by LDH efflux assay. (C-E) The alterations of MDA (C), 4-HNE (D), and ROS (E) were measured upon ferroptosis regulation. (F) Representative images of the fluorescent probe FerroOrange showing intracellular Fe2+ levels in podocytes. Scale bars, 20 μm. (G) Immunoblots were quantified using ImageJ and normalized to GAPDH. The data is displayed as the average plus or minus the standard deviation. Significance levels are denoted as p < 0.01 for a high level of significance and p < 0.001 for an even higher level of significance Ferroptosis contribute to DDP-induced podocyte injury (A) Cell viability were determined by the MTT assay. (B) Cell damage was measured by LDH efflux assay. (C-E) The alterations of MDA (C), 4-HNE (D), and ROS (E) were measured upon ferroptosis regulation. (F) Representative images of the fluorescent probe FerroOrange showing intracellular Fe2+ levels in podocytes. Scale bars, 20 μm. (G) Immunoblots were quantified using ImageJ and normalized to GAPDH. The data is displayed as the average plus or minus the standard deviation. Significance levels are denoted as p < 0.01 for a high level of significance and p < 0.001 for an even higher level of significance ALKBH5 bidirectionally regulates ferroptosis of tubular epithelial cells induced by DDP Our previous knockout and knock-in animal studies confirmed that ALKBH5 mediates DDP-induced renal injury. A logical flaw was whether ALKBH5 is directly involved in the regulating of DDP-induced ferroptosis. Here, we designed in vitro podocyte experiments to observe the effects of primary transfer interference or overexpression of ALKBH5. Western blot analysis confirmed the success of the transfection strategy (Fig. 5A). The injury phenotype of transfected cells treated with DDP was consistent with that of animals, and knockdown of ALKBH5 alleviated podocyte injury, whereas its overexpression aggravated podocyte injury (Fig. 5B, C). Simultaneous examination of the relevant indicators of ferroptosis showed that these two strategies caused opposite ferroptosis phenotypes (Fig. 5D–G). The results of ferrous ferroorange staining and ferroptosis-related protein analysis confirmed our hypothesis. These results provided key evidence that ALKBH5 directly regulates ferroptosis-related pathways.Fig. 5ALKBH5 directly regulates ferroptosis-related pathways under DDP administration. (A) The level of ALKBH was determined by western blotting. (B) Cell viability were determined by the MTT assay.(C) Cell damage was measured by LDH efflux assay.(D-G) The alterations of MDA (D), GSH (E), ROS (F) and 4-HNE (G) were measured upon ferroptosis regulation. (H) Representative images of the fluorescent probe FerroOrange showing intracellular Fe2+ levels in podocytes.Scale bars, 20 μm.Proteins associated with ferroptosis were quantified through immunoblots using ImageJ and then standardized against GAPDH.The data is displayed as the average plus or minus the standard deviation. Significance levels are denoted as p < 0.01 for a high level of significance and p < 0.001 for an even higher level of significance ALKBH5 directly regulates ferroptosis-related pathways under DDP administration. (A) The level of ALKBH was determined by western blotting. (B) Cell viability were determined by the MTT assay.(C) Cell damage was measured by LDH efflux assay.(D-G) The alterations of MDA (D), GSH (E), ROS (F) and 4-HNE (G) were measured upon ferroptosis regulation. (H) Representative images of the fluorescent probe FerroOrange showing intracellular Fe2+ levels in podocytes.Scale bars, 20 μm.Proteins associated with ferroptosis were quantified through immunoblots using ImageJ and then standardized against GAPDH.The data is displayed as the average plus or minus the standard deviation. Significance levels are denoted as p < 0.01 for a high level of significance and p < 0.001 for an even higher level of significance ALKBH5 inhibition protects against DDP-induced renal injury Our results suggest that pharmacological inhibition of ALKBH5 may be an effective treatment strategy for DDP nephropathy. The anticancer activity of ALKBH5 inhibitors has been confirmed in preclinical studies and clinical trials. Therefore, we investigated the effect of an ALKBH5 blocker on DDP kidney damage in live animals (Fig. 6A). Western blotting showed that blocking ALKBH5 was just as successful as reducing ALKBH5 expression in alleviating kidney injury caused by DDP treatment (Fig. 6B). Serum markers of renal function were significantly altered, indicating improved renal function (Fig. 6C–E). Following treatment, all biochemical ferroptosis markers decreases synchronously (Fig. 6F–K).Fig. 6ALKBH5 inhibition improved parameters in DDP-induced nephropathy in mice. (A) Schematic representation of drug injection strategy. (B) Validation of the suppressive efficiency of ALKBH inhibitors by Western blot.(C-E) Blood urea nitrogen (C), creatinine (D) and uranary albuminuria/creatinine ratios(ACR) (E) were measured in plasma after DDP and/or ALKBH5 inhibitors tail vein administration in the indicated groups. Changes in levels of iron, MDA, GSH, SOD, and 4-HNE were assessed following the inhibition of ALKBH5. Ferroptosis-associated protein immunoblots were quantified with ImageJ and then standardized against GAPDH.The data is displayed as the average plus or minus the standard deviation.Significance levels: p < 0.05, p < 0.01, p < 0.001 ALKBH5 inhibition improved parameters in DDP-induced nephropathy in mice. (A) Schematic representation of drug injection strategy. (B) Validation of the suppressive efficiency of ALKBH inhibitors by Western blot.(C-E) Blood urea nitrogen (C), creatinine (D) and uranary albuminuria/creatinine ratios(ACR) (E) were measured in plasma after DDP and/or ALKBH5 inhibitors tail vein administration in the indicated groups. Changes in levels of iron, MDA, GSH, SOD, and 4-HNE were assessed following the inhibition of ALKBH5. Ferroptosis-associated protein immunoblots were quantified with ImageJ and then standardized against GAPDH.The data is displayed as the average plus or minus the standard deviation.Significance levels: p < 0.05, p < 0.01, p < 0.001 Adeno-associated virus vector mediated ALKBH5 inhibition is a powerful tool in the treatment of DDP nephropathy Next, we investigated whether adeno-associated virus (AAV) suppression treatment could reverse the established DDP nephropathy. To confirm this observation, ALKBH5 was downregulated by renal vein injection of AAV shRNA targeting ALKBH5 (ALKBH5-shRNA) or AAV control (Control-shRNA) into DDP-treated mice (Fig. 7A). The AAV vectors also expressed a transgene encoding green fluorescent protein (GFP), and three weeks after AAV injection, proper AAV injections in the kidney were confirmed by fluorescence imaging (Fig. 7B). Renal ALKBH5 protein knockdown was confirmed by immunoblot analysis, which showed that the mice expressed at least 60% less protein following AAV administration (Fig. 7C). Serum markers of renal function were significantly reduced, indicating alleviated DDP-induced renal injury and improved renal function (Fig. 7D–F). Following treatment with largely restored renal function, all biochemical ferroptosis landmarks were restored synchronously (Fig. 7G–L).Fig. 7ALKBH5-based gene therapy improved parameters in DDP-induced nephropathy in mice. (A) Schematic paradigm showing renal infection strategy by AAV injection intravenously in the tail vein. (B) Green fluorescence was observed under the fluorescence microscope to confirm the effectiveness of AAV virus infection in kidney tissue.Scale bars, 50 μm. (C) Validation of the suppressive efficiency of ALKBH inhibitors by western blot. (D-F) Blood urea nitrogen (D), creatinine (E) and uranary albuminuria/creatinine ratios(ACR) (F) were measured in plasma after DDP and/or ALKBH5 geen targeting therapy in the indicated groups. Changes in levels of iron (G), MDA (H), GSH (I), SOD (J), and 4-HNE (K) were assessed following treatment targeting the ALKBH5 gene. Ferroptosis-associated protein immunoblots were quantified with ImageJ and then standardized against GAPDH. The data is displayed as the average plus or minus the standard deviation. Significance levels: p < 0.05, p < 0.01, p < 0.001 ALKBH5-based gene therapy improved parameters in DDP-induced nephropathy in mice. (A) Schematic paradigm showing renal infection strategy by AAV injection intravenously in the tail vein. (B) Green fluorescence was observed under the fluorescence microscope to confirm the effectiveness of AAV virus infection in kidney tissue.Scale bars, 50 μm. (C) Validation of the suppressive efficiency of ALKBH inhibitors by western blot. (D-F) Blood urea nitrogen (D), creatinine (E) and uranary albuminuria/creatinine ratios(ACR) (F) were measured in plasma after DDP and/or ALKBH5 geen targeting therapy in the indicated groups. Changes in levels of iron (G), MDA (H), GSH (I), SOD (J), and 4-HNE (K) were assessed following treatment targeting the ALKBH5 gene. Ferroptosis-associated protein immunoblots were quantified with ImageJ and then standardized against GAPDH. The data is displayed as the average plus or minus the standard deviation. Significance levels: p < 0.05, p < 0.01, p < 0.001 Discussion Despite clinicians implementing appropriate intervention measures when prescribing DDP, approximately one-third of patients experience nephrotoxicity, thereby restricting its clinical utility. Consequently, it is imperative to elucidate the fundamental mechanisms underlying cisplatin-induced nephrotoxicity and establish efficacious treatment modalities. Blood urea nitrogen and serum creatinine levels are commonly used as indicators for the clinical assessment of renal function (Liu et al. 2024). When the renal function is impaired, there is a rapid increase in the levels of these two indicators. Blood samples were collected at the end of the experiment to analyze the kidney function of mice in our study. These findings showed that an AKI model was successfully created by administering DDP to mice. To explore the root molecular causes of this damage, a study was conducted to analyze the expression of ALKBH5 over time using experiments both in living organisms and in a controlled cell culture environment. Both in vivo and in vitro studies have shown a time-dependent increase in ALKBH5 expression, suggesting the possible involvement of ALKBH5 in AKI damage progression. Prior research on DDP nephrotoxicity has established the significant impact of oxidative stress, which is theoretically consistent with the dysregulation of oxidative stress being a hallmark feature of ferroptosis (Yuan et al. 2024). Ferroptosis is the predominant mechanism of cell death in renal tubular cells of renal ischemia–reperfusion mice (Tao et al. 2024). In a mouse model of diabetic nephropathy, significant alterations were observed in ferroptosis-related markers within the kidney (Li et al. 2024). These observations suggest that ferroptosis is a critical factor in renal tubular injury in various kidney diseases, with the subsequent release of inflammatory molecules and activation of damage-associated molecular patterns contributing to organ damage. This theoretically explains the phenomenon of DDP-induced renal injury observed in previous studies. ALKBH5 is recognized as a crucial element in multiple organ injuries. Research conducted by Chen et al. demonstrated that inhibition of ALKBH5 effectively mitigates renal ischemia–reperfusion injury and confirmed the involvement of ferroptosis (Chen et al. 2023). This supports the reliability of our study: 1. ALKBH5 is indeed expressed in the kidney tissue, and our in vitro results further confirm that ALKBH5 expression can be induced by DDP in renal tubular cells; 2. ALKBH5 also plays a key role in regulating ferroptosis in DDP-induced renal injury. In our study, the role of ALKBH5 was confirmed in transgenic overexpression and knockout mice. Following DDP administration, the animals exhibited contrasting renal injury phenotypes, with either exacerbated or ameliorated symptoms. Renal tubular epithelial cell injury, a recognized pathological characteristic of DDP-induced AKI, is characterized by elevated ROS levels in renal tubular epithelial cells. The findings of ROS staining aligned with those of renal function injury, bolstering our confidence in investigating its potential association with ferroptosis. Our morphological findings are consistent with the existing literature on ferroptosis, indicating that the cell and nuclear membranes remain intact in ferroptotic cells (Walravens et al. 2024). Ferroptosis relies on iron and ROS to cause cell death and is associated with the accumulation of lipid peroxidation products and excessive free iron. In addition to the existence of unbound Fe2+ inside cells, which can produce a substantial amount of ROS through the Fenton reaction, causing oxidative harm to cells, there is also a noteworthy accumulation of lipid peroxidation byproducts, such as malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE) (Mu et al. 2023). The accumulation of these lipid peroxidation products increases during the progression of ferroptosis, thereby serving as indicators of the extent of ferroptotic damage. In vivo analysis of ferroptosis-related markers revealed that DDP administration led to notable alterations in renal tubular tissue associated with ferroptosis. Notably, the ferroptosis-related pathological changes induced by cisplatin treatment were significantly attenuated in ALKBH5 knockout animal models. This raises two crucial questions: 1. Whether ferroptosis plays a decisive role in DDP-induced renal tubular injury; and 2. What are the influences of the changes in ALKBH5 levels on ferroptosis regulation. To answer these questions, we first explained the important role of ferroptosis in cisplatin-induced damage to renal tubular cells using ferroptosis inducers and inhibitors in a laboratory setting. In this study, we demonstrated that DDP exposure causes ferroptosis in HK-2 cells. However, after pretreatment with DFP and fer-1, two specific ferroptosis inhibitors, the ferroptosis level of renal tubular HKC cells decreased significantly, which effectively reduced the staining intensity of ferrous-specific markers in DDP-treated HKC cells, alleviated the degree of lipid peroxidation, and significantly altered the ferroptosis pathway protein level. These results suggest that the damage caused by DDP in HK-2 cells relies on iron, which is consistent with earlier findings in different cell lines (Cai et al. 2024). Furthermore, we conducted in vitro experiments utilizing the two-way regulation of ALKBH5 expression to assess its impact on the indicators associated with ferroptosis. These results indicate that ALKBH5 is involved in controlling iron-induced cell death, providing evidence that ALKBH5 is involved in DDP nephrotoxicity through a complete ferroptosis mechanism. The aforementioned validation of ALKBH5's involvement indicates its potential as a viable target for drug delivery. By screening potential inhibitors of ALKBH5 based on the pertinent literature (Lee et al. 2021; Sun et al. 2023), implementing a protective inhibition intervention prior to modeling, and confirming its efficacy in treating DDP-induced AKI in an in vivo model, we demonstrated its therapeutic potential. Additionally, advancements in gene therapy have shown promise for the treatment of renal diseases (Peek and Wilson 2023). Adeno-associated virus (AAV) is a nonpathogenic viral vector that has been utilized in gene therapy for various organ diseases and has progressed to clinical trials. Despite the rapid advancements in gene therapy for other conditions, the development of gene therapy for kidney diseases has lagged significantly. The minimally invasive nature and high specificity of gene therapy have prompted investigations into the potential of targeting ALKBH5 using this approach. In this study, an enhanced renal vein injection method was utilized, in contrast to the conventional tail vein injection (Rubin and Barry 2020), resulting in efficient exogenous gene transfer to the glomerulus and proximal tubules. The efficacy of this intervention strategy was validated using western blotting and fluorescence analysis, thereby expanding the repertoire of intervention techniques for AKI and providing crucial preclinical evidence. Although this study has made progress in understanding the mechanism of cisplatin-induced renal injury and potential intervention strategies, there are still some problems that need to be resolved in a follow-up study. Our study found that ALKBH5 is involved in ferroptosis; however, its specific methylation regulation remains unclear. Although previous studies have shown that SLC7A11 (Luo et al. 2023), a key protective factor against ferroptosis, can be regulated by ALKBH5, whether this mechanism exists in the kidney and whether other mechanisms exist remain to be clarified. On the other hand, ALKBH5 is also involved in the occurrence of tumor progression (Hu et al. 2022; Zhai et al. 2023). When using specific inhibitors for drug intervention, we need to consider whether the inhibitors affect tumor growth. The AAV-targeted treatment strategy proposed in our study suggests that interference that affects the efficacy of antitumor drugs can be avoided. It is also worth noting that the sexual dimorphism in cisplatin-induced nephrotoxicity has been documented in both clinical and preclinical studies (Chen et al. 2017; Eshraghi-Jazi and Nematbakhsh 2022). Naseem et al. demonstrated that female mice exhibit greater resistance to cisplatin-induced renal toxicity than male mice, which is attributed to a more robust antioxidant system in females (Salman and Naseem 2015). Animals of both sexes were used in this study. Both sexes of the WT animals exhibited impaired renal function-related blood marker alterations at the selected cisplatin dose, and these changes were ameliorated in the corresponding knockout animals. This suggests that the ALKBH5 knockout-mediated renoprotective effect operates in a sex-independent manner. However, we did not delve into the differences in the protective effects between the sexes, which warrants further investigation in future studies. In conclusion, this is the first study to reveal the function of ALKBH5 in DDP-induced AKI by controlling ferroptosis. Utilizing ALKBH5 inhibitors or targeted gene therapy as preventive measures may effectively mitigate renal damage following DDP treatment, indicating that ALKBH5 is a promising therapeutic target for addressing human DDP nephrotoxicity. These findings offer a foundation for the development of adjunctive therapies for renal protection, and present a novel approach for the identification and utilization of anti-AKI medications.